Invion Ltd. (AU:IVX) has released an update.
Invion Ltd has secured up to $6.8M in institutional funding to advance its cancer and infectious disease programs, including a partnership with South Korean pharma Hanlim for glioblastoma treatment research. The company has also addressed ethics issues delaying its skin cancer trial, anticipating patient recruitment later this year, and expanded its patent portfolio, signaling a strengthening of its developmental and commercial capabilities in the biotech sector.
For further insights into AU:IVX stock, check out TipRanks’ Stock Analysis page.
